Therapeutic and prognostic value of repeat transurethral resection for high-grade Ta bladder cancer: a propensity score matching analysis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
High-grade Ta bladder cancer, although anatomically confined to the mucosa, exhibits aggressive biological behavior with high recurrence rate and progression risks. The role of repeat transurethral resection of bladder tumor (Re-TURBT) in this specific population remains controversial. This retrospective cohort study aimed to evaluate the therapeutic and prognostic value of Re-TURBT for high-grade Ta non-muscle-invasive bladder cancer (NMIBC) using propensity score matching (PSM) analysis. A total of 324 patients with pathologically confirmed high-grade Ta urothelial carcinoma who underwent initial TURBT from January 2014 to June 2023 were included in this study. Among them, 196 underwent Re-TURBT within 2-6 weeks, whereas 128 did not. PSM was performed in a 1:1 ratio using a caliper width of 0.10, resulting in 70 matched pairs with comparable baseline characteristics. Recurrence-free survival (RFS) was defined as primary outcome. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the residual tumor detection rate. In the Re-TURBT group, residual tumor was detected in 29.6% of patients, with pathological upstaging observed in 8.6% of cases (7.1% to T1 and 1.5% to T2). The Re-TURBT group showed significantly lower recurrence rates (14.3% vs. 50.0%; P
Fields of Study & Subjects
Bladder and Urothelial Cancer Treatments
Urinary and Genital Oncology Studies
Urinary Bladder and Prostate Research
Publication details
- Journal / source
- American Journal of Cancer Research
- Volume
- 16
- Issue
- 3
- Pages
- 771–795
- Publication date
- 1 January 2026
- Language
- EN